【产品介绍】：

生物活性：Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Lenvatinib-d5 相关抗体:
FGFR2/CD332 Antibody
c-Kit Antibody (YA502)
Phospho-PDGFR beta (Y740) Antibody
VEGF Receptor 2 Antibody (YA014)
FGFR1 Antibody
FGFR1 Oncogene Partner Antibody
FGFR2 Antibody
FGFR3 Antibody
PDGFR alpha Antibody
FGF2 Antibody
VEGF Receptor 1 Antibody
VEGFA Antibody
VEGF Receptor2 Antibody
FGF1 Antibody (YA1430)
PDGF B Antibody (YA1556)
FGFR4 Antibody (YA1588)
PLGF Antibody (YA1812)
PDGFR beta Antibody (YA1925)
VEGFD Antibody (YA2385)
FGF19 Antibody (YA2672)
TACC3 Antibody (YA2921)
Phospho-PDGFR beta (Tyr740) Antibody (YA3062)
FGF21 Antibody (YA3276)
c-Kit Antibody
SCF Antibody
PGF Antibody (YA1434)
Neuropilin 1 Antibody (YA1831)
VEGFB Antibody (YA2627)
分子量：431.88
Formula：C21H14D5ClN4O4
非标记 CAS：417716-92-8
中文名称：乐伐替尼 d5
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (531 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Kudo M, et al. Lenvatinib versus Bay 43-9006 in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.
 [Content Brief]
[3]. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.
 [Content Brief]
[4]. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671.
 [Content Brief]
[5]. Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.
 [Content Brief]